Pharmacy Benefit Managers (PBMs) are often painted as the villains hoarding rebates and driving drug prices higher. Yet, a closer look reveals that PBMs are among the most effective tools we have to bring down patients’ out‑of‑pocket costs, inject transparency into pricing, and swiftly adapt to new therapies. Consider three recent developments that underscore their evolving value: CVS Caremark’s new cost‑plus model, industry‑wide savings data, and innovations in managing specialty medications.
This year, CVS Caremark rolled out its “TrueCost” and “CostVantage” pricing models, marking a watershed moment in PBM transparency. TrueCost applies an acquisition-based, drug‑level net cost pricing model—meaning the price displayed at the pharmacy counter reflects what CVS actually paid, plus a modest dispensing and admin fee. Gone are the surprise list‑price copays and hidden markups. According to CVS, the average member now pays just $7.26 for a 30‑day supply of medication—representing a 36 percent reduction in out‑of‑pocket costs between 2016 and 2023—even as overall drug list prices have escalated at an annual rate around 7 percent. This transparent model doesn’t just help patients—it offers predictability for employers and health plans, since drug-level, multi-year net cost guarantees remove rebate uncertainty.
Zoom out from CVS, and the results are equally compelling. PBMs work with employers and insurers to negotiate deeper discounts than any individual purchaser could secure alone. As of early 2025, PBMs are estimated to save employers and members around $1,040 per person annually, contributing roughly $145 billion in total value to the health care system each year. Employers overwhelmingly report high satisfaction—over 85 percent rate PBMs highly for cost‑effectiveness, transparency, and negotiation power. These are not abstract numbers; they reflect tangible monthly savings on treatments that patients rely on.
The third example comes from specialty and high-cost drugs, where PBMs and related innovators are rewriting the rules to help patients receive more reliable, affordable care. By steering patients toward hospital‑based 340B pharmacy programs—structures originally designed to support low‑income patient care—PBMs and benefit firms like Rescription and Liviniti are cutting employer costs on specialty medications by as much as 33 percent in pilots like Baton Rouge General Medical Center, where rheumatoid arthritis therapy dropped from roughly $4,830 to $600 per month. This novel channel not only saves money but expands the reach of hospital clinics, reinforcing community care habitats. All equity‑enhancing and cost‑cutting goals at once.
These trends paint a powerful picture: PBMs are transforming from opaque hidden structures into patient‑centric engines of affordability.
Critics allege PBMs obscure their deals or that spread-pricing hurts local pharmacies. Yet CVS’s model, along with industry-wide satisfaction and the integration of distributed care via 340B, shows how PBMs can adapt to concerns—reducing cross‑subsidization, enhancing transparency, and bolstering reimbursements for independent pharmacies to prevent closures. Yes, reforms and government oversight are essential, but market innovation is delivering change now.
PBMs have a stronger incentive than ever to align with patient and employer interests—not hide behind opacity. They wield negotiating power to lower cost-sharing at the cash register, create greater predictability in health plan budgets, and open new pathways for disruptive, specialty‑drug care. These are measurable outcomes already shifting the landscape: copays under $10, $1,000+ annual savings per member, and a 33 percent reduction in specialty drug costs in pilot programs involving real patients.
Where healthcare promises often outpace delivery, PBMs offer a rare win-win. They deliver lower costs, maintain drug access, and drive smarter, disruptive care models that benefit patients today, not merely ten years hence.
Victor Lopez is the CEO at Imperio Strategies.
